15th EU HIV & Hepatitis – Presentations

Wednesday, 7 June
  Session 2:
Lecture: Advances in topical protection against HIV-1 infection
R. Cranston, MD, FRCP, IrsiCaixa AIDS Research Institute, Spain
  Abstract presentations
  HIV-1 B subtype genetically diverges over the years 2003-2016 and changes its pathogenic potential  (presentation not available)
C. Alteri, Italy
  Integrase Inhibitors based regimens limit HIV-1 tropism evolution  (presentation not available)
R. Scutari, Italy
  Virological failure to protease inhibitors in monotherapy is linked to the presence of signature mutations in gag without changes in HIV-1 replication
O. Blanch - Lombarte, Spain
  Frequency of occurrence of HIV-1 superinfection in MSM
L. Hebberecht, Belgium
  Session 2:
Lecture: The new WHO global action plan 2016-2021 (presentation not available)
S. Bertagnolio, MD, WHO, Switzerland
  Abstract presentations
  Molecular epidemiology and patterns of transmitted drug resistance in HIV-1 infected African migrants followed-up in Portugal
 A. Abecasis, Portugal
  High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: Evidence for country and regional level transmission networks
D.Paraskevis, Greece
  Trends for transmitted drug resistance and prevalence of non-B subtypes in recent HIV infections – results from the national molecular surveillance, Germany 2013 - June 2016
A. Hauser, Germany
  Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected treatment-naïve patients from two large databases in France and Italy
A. G. Marcelin, France
  Session 3:
Lecture: New therapeutic strategies
P. Lampertico, MD, University of Milan, Italy
Lecture: Risk and management of HBV reactivation
C. Den Hoed, MD, PhD Erasmus MC, the Netherlands
  Abstract presentations
  The extent of genetic variability in HBsAg C-terminus profoundly affects HBsAg levels in eAg-negative chronic HBV genotype D infection
A. Battisti, Italy

Positively charged mutations in HBsAg C-terminus are tightly correlated with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain (presentation not available)
Dr. R. Salpini , Italy

Thursday, 8 June
  Session 4:
Lecture: Remaining and emerging challenges for HIV clinical management (presentation not available)
R. Paredes, MD, PhD,  IrsiCaixa AIDS Research Institute, Spain
  Abstract presentations
  Analysis of the association of HIV-1 low level viremia and treatment failure of antiretroviral therapy  (presentation not available)
N. Lübke, Germany
  Effectiveness of protease inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa
A. M. Geretti, United Kingdom
  Impact of M184V resistance mutation on virological efficacy of lamivudine-based maintenance dual therapies: an Italian ARCA cohort study
R. Gagliardini, Italy
  A low genetic barrier and reactivation of pre-existing proviruses harboring a single INSTI-RAM explains virological failure during dolutegravir maintenance monotherapy (presentation not available)
J. Van Kampen, the Netherlands
  Sensitivity of a novel translocation defective reverse transcriptase inhibitor, EFdA in comparison to second generation NNRTIs, Etravirine and Rilpivirine on diverse HIV-1 subtypes
U.Neogi, Sweden
  Session 5:
The virologist's perspective
A. G. Marcelin, PharmD, PhD, Pierre et Marie Curie University, France
The clinician's perspective
A. De Luca, MD, University of Siena, Italy
The pharmacologist's perspective
G. Di Perri, MD, PhD,  University of Turin, Italy
  12th International Workshop on Hep C Resistance - Session 1:
Lecture: Acute Hepatitis C: Treatment as prevention 
C.Boucher, MD, PhD, Erasmus MC, the Netherlands

Lecture: Clinical relevance of hepatitis C drug resistance 
F.Ceccherini - Silberstein, PhD,  University of Rome Tor Vergata, Italy

  Abstract presentations
  Resistance-associated and fitness-associated substitutions on NS3, NS5A and NS5B genes in real-life HCV positive patient failed to 3D therapy.
N.Marascio, Italy
  Real-life efficacy of HCV-retreatment after DAA-failure: the role of NS5A-resistance
V. Cento, Italy
  Retreatment of DAA failures with approved regimens and resistance information in a real life setting: data form the HepcResp Gehep004 cohort
F. Garcia, Spain
  Clinical relevance of accurate HCV genotype and subtype assignment by HCV Sanger and next generation sequencing in the era of new direct acting antiviral agents
M. Aragri , Italy
  12th International Workshop on Hep C Resistance - Session 2:
Lecture: The German HCV drug resistance (RAS) database (presentation not available)
J. Vermehren, MD,  University Hospital Frankfurt , Germany

Lecture: The European Hepcare project
V. Cento, PhD,  University of Rome Tor Vergata, Italy


Friday, 9 June
  Session 6:
Lecture: Clinical use of HIV-DNA quantity and resistance testing
M.Zazzi, MSc, University of Siena, Italy
  Abstract presentations
  HIV-1 drug resistance testing using Nanopore technology – a long-range low error sequencing approach using rolling circle amplification (presentation not available)
M. Daeumer, Germany
  Next generation sequencing in reverse transcriptase and protease of HIV-1 helps to discriminate recent from chronically infected newly diagnosed patients
J. A.  Fernandez - Caballero Rico , Spain
  Patients with multiresistant virus : A limited number, but a remarkable deal. Introduction: Real life case
M. Santoro, PhD, University of Rome Tor Vergata , Italy
  Session 7:
Lecture: Update of cure strategies
M. Nijhuis, PhD, University Medical Centre Utrecht , the Netherlands
Lecture: Is HIV management moving towards Personalized Medicine ?
C .F.Perno, MD, PhD, University of Rome Tor Vergata, Italy
Lecture: Long-acting injectables
I.McGowan, MB, ChB, Dphil, MD, FRCP, University of Pittsburg , USA